Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02976038 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
A Phase 2 study, sponsored by Stealth BioTherapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT02976038 is a Phase 2 study that was terminated before completion, run by Stealth BioTherapeutics. The registered enrollment target is 28 participants.
The verdict
NCT02976038, a Phase 2 study, was terminated before completion, sponsored by Stealth BioTherapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a Phase 2 Open-Label extension study to evaluate the long term safety and tolerability of daily elamipretide injections in patients with genetically confirmed Primary Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial
Interventions
- DRUG elamipretide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-04-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02976038
The ClinicalTrials.gov registry entry for NCT02976038 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stealth BioTherapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which elamipretide is the first listed.
NCT02976038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02976038 about?
NCT02976038 is a clinical study titled "Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)". This is a Phase 2 Open-Label extension study to evaluate the long term safety and tolerability of daily elamipretide injections in patients with genetically confirmed Primary Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial
What is the current status of trial NCT02976038?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2016-12. Estimated completion is 2020-04-09.
What interventions are being tested in trial NCT02976038?
The interventions under investigation include: elamipretide (DRUG).
Who is sponsoring clinical trial NCT02976038?
This trial is sponsored by Stealth BioTherapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.